 |
2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid |
|---|---|
| Trade Name | |
| Orphan Indication | Huntington disease |
| USA Market Approval | USA |
| USA Designation Date | 2014-06-02 00:00:00 |
| Sponsor | Pfizer Inc.;445 Eastern Point Road;Groton, Connecticut, 06340 |
Related Access Program